Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

LOL, but we can dispense with the fifth item on your list: At this point, it would hardly even matter if Teva got FDA approval for generic Lovenox. NVS/MNTA have already sued Teva for patent infringement and the Court would almost certainly merge this case with the suit against Amphastar/WPI. Moreover, the effect on price and market share from having another generic entrant in the marketplace would be small, probably costing MNTA less than $1M in lost royalties each quarter.

p.s. I still think Teva's Lovenox ANDA probably isn't approvable for the reasons set forth in #msg-66767716.